Asmanex Twisthaler (Mometasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2019 Category: Drugs & Pharmacology Source Type: news
Asmanex Twisthaler (Mometasone Furoate Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2019 Category: Drugs & Pharmacology Source Type: news
mometasone furoate (Nasonex)
Title: mometasone furoate (Nasonex)Category: MedicationsCreated: 6/6/1999 12:00:00 AMLast Editorial Review: 3/25/2019 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - March 25, 2019 Category: Allergy & Immunology Source Type: news
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon.
The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches trial of drug-coated sinus balloon appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Featured Otolaryngology Ear, Nose & Throat Pharmaceuticals Wall Street Beat intersectent Source Type: news
How Can Nanotechnologies Aid Implantable Drug-Delivery Systems?
Implantable technologies have come a long way over the years, and advancements in micro and nanotechnologies have helped device developers continue to push the envelope even further. Within the realm of drug delivery, advances in nanotechnologies have consistently improved patient outcomes by enabling sustained drug delivery to help treat chronic conditions. These scalable technologies have even offered localized drug delivery that can further improve bioavailability.
While many of these technologies offer a variety of opportunities, we’re still eagerly awaiting to see the impact of these advancements onc...
Source: MDDI - November 29, 2018 Category: Medical Devices Authors: Kristopher Sturgis Tags: BIOMEDevice San Jose Implants Source Type: news
Mometasone Furoate (Elocon) 0.1% Ointment (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - June 13, 2018 Category: Drugs & Pharmacology Source Type: news
Asmanex Twisthaler (Mometasone Furoate Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 5, 2018 Category: Drugs & Pharmacology Source Type: news
Intersect ENT launches Sinuva steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery.
Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to 90 days.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT launches Sinuva steroid-releasing sinus implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants Otolaryngology Ear, Nose & Throat Pharmaceuticals Regulatory/Compliance Wall Street Beat intersectent Source Type: news
Sinuva (Mometasone Furoate) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 21, 2017 Category: Drugs & Pharmacology Source Type: news
Intersect ENT Announces FDA Approval of Sinuva (mometasone furoate) Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 11, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that it has received approval from the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 11, 2017 Category: Drugs & Pharmacology Source Type: news
Intersect ENT wins FDA nod for Sinuva polyp-disease-treating sinus implant
Intersect ENT (NSDQ:XENT) said today it won FDA approval for its Sinuva mometasone furoate sinus implant designed to treat recurrent nasal polyp disease in patients who have previously had ethmoid sinus surgery.
The Sinuva device is designed to be implanted during a routine physician office visit and expands into the sinus cavity to deliver an anti-inflammatory steroid directly to the site of the polyp disease for 90 days.
Read the whole story on our sister site, Drug Delivery Business
The post Intersect ENT wins FDA nod for Sinuva polyp-disease-treating sinus implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 11, 2017 Category: Medical Devices Authors: Fink Densford Tags: Drug-Device Combinations Food & Drug Administration (FDA) Otolaryngology Ear, Nose & Throat Regulatory/Compliance intersectent Source Type: news
Elocon (Mometasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2017 Category: Drugs & Pharmacology Source Type: news
Elocon Lotion (Mometasone Furoate Lotion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2017 Category: Drugs & Pharmacology Source Type: news
Elocon Ointment (Mometasone Furoate Ointment) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 27, 2017 Category: Drugs & Pharmacology Source Type: news
Amneal Introduces Its First Nasal Spray: Generic Nasonex(R)
BRIDGEWATER, N.J., April 11, 2017 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals LLC has launched mometasone furoate nasal spray, the company's first pharmaceutical product in spray form. Mometasone furoate, available in 50 mcg/spray... Biopharmaceuticals, Generics, Drug Delivery, Product Launch Amneal Pharmaceuticals, mometasone furoate, nasal spray, Nasonex (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 11, 2017 Category: Pharmaceuticals Source Type: news
